Pharmacokinetic parameters were calculated using standard non-compartmental methods. The Cmax and the time to reach Cmax (tmax) were derived from the plasma concentration–time curves. Elimination rate constant (λz) was calculated by linear regression of the terminal linear portion of the ln(concentration–time) curve, and the apparent elimination half-life (t1/2) was determined as 0.693/λz. The AUC from time 0 to the last timepoint (AUC0–t) was calculated using linear trapezoidal method. The AUC from 0 to infinity (AUC0–∞) was calculated as AUC0–t + Ct/λz, where Ct is the last measurable concentration. Phoenix WinNonlin software version 6.3 (Pharsight Corporation, St Louis, MO, USA) was used for all pharmacokinetic analyses.
Phoenix winnonlin software version 6
Manufactured by Pharsight
Sourced in United States
Phoenix WinNonlin software version 6.3 is a data analysis tool designed for pharmacokinetic and pharmacodynamic modeling. It provides a platform for the analysis and visualization of drug concentration-time data.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using phoenix winnonlin software version 6
1
Pharmacokinetic Parameters Analysis
2
Pharmacokinetics and Gut Microbiome Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Data for each group are presented as mean ± SD. Statistical significance of different formulations were measured by one-way analysis of variance (ANOVA) followed by the Tukey Kramer multiple comparison test, using SPSS software version 14.0 (SPSS, Chicago, IL, USA), and the statistical significance was expressed by a p-value of less than 0.05. The main pharmacokinetic parameters of MHO7 was fitted by the average mean of a group in each time point with the Phoenix WinNonLin software version 6.3 (Pharsight, Cary, NC, USA). The gut microbiome analysis was performed using the free online platform of Majorbio Cloud Platform (www.majorbio.com ).
3
Pharmacokinetics of Single and Repeated Dosing of AMG 208
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
AMG 208 pharmacokinetics was evaluated after a single dose and after 28 days of repeated daily dose administrations. AMG 208 plasma concentrations were determined by liquid chromatography-tandem mass spectrometry from samples collected predose, 0.5, 1, 2, 4, 8, 24, and 48 or 72 hours after dosing on day 1, and pre-dose, 0.5, 1, 2, 4, 8, 24, and 48 hours on day 28. Pharmacokinetic parameters of observed Cmax, time of Cmax (tmax), and AUC0–24h were determined by noncompartmental analysis using Phoenix WinNonlin software version 6.3 (Pharsight®, St. Louis, MO). AMG 208 accumulation was estimated as a ratio of AUC0–24h on day 28 relative to day 1 for patients who remained on the study for ≥28 days.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!